Literature DB >> 1375133

Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.

J L Abbruzzese1, P Frost.   

Abstract

2'-Deoxy-5-azacytidine (5-aza-CdR) and cisplatin interact to produce synergistic cytotoxicity against many human tumor cell lines. Preliminary experiments designed to explore the mechanism of this synergy suggested a poor correlation between synergy and the degree of genomic hypomethylation measured following exposure to 5-aza-CdR. Subsequent studies using plasmid DNA suggested that rather than DNA hypomethylation, incorporation of 5-aza-CdR into DNA mediated increased cisplatin binding to DNA and could therefore be essential to the synergistic interaction between these two agents. In this series of experiments, we evaluated the degree of synergy with cisplatin produced against two human melanoma cell lines by two additional antimetabolites that were chosen on the basis of their biochemical properties. In addition, we investigated the synergy between 5-aza-CdR and cisplatin in parental and 5-aza-CdR-resistant murine cell lines, which differed in their sensitivity to 5-aza-CdR and DNA methylation status but incorporated similar amounts of 5-aza-CdR into DNA when exposed to this antimetabolite. In the studies testing additional antimetabolites, cytosine arabinoside, which is incorporated into DNA but does not hypomethylate it, produced synergy with cisplatin that was similar or superior to that obtained using 5-aza-CdR. With 3-deaza-adenosine, which is not incorporated into DNA but produces DNA hypomethylation through inhibition of S-adenosylhomocysteine hydrolase, a primarily antagonistic interaction was observed in the two cell lines studied. In the 5-aza-CdR-sensitive and -resistant cell lines, a very similar synergistic interaction was documented for 5-aza-CdR and cisplatin despite the significant difference observed in DNA methylation levels. Taken as a whole, these data suggest that DNA hypomethylation was not critical to the synergistic cytotoxicity produced by 5-aza-CdR and cisplatin. This finding suggests additional strategies that could further modulate this interaction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375133     DOI: 10.1007/bf00686482

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance.

Authors:  L A Michalowsky; P A Jones
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

2.  Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase.

Authors:  R L Momparler; D Derse
Journal:  Biochem Pharmacol       Date:  1979-04-15       Impact factor: 5.858

3.  Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine.

Authors:  F Creusot; G Acs; J K Christman
Journal:  J Biol Chem       Date:  1982-02-25       Impact factor: 5.157

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.

Authors:  B B Aggarwal; T E Eessalu; P E Hass
Journal:  Nature       Date:  1985 Dec 19-1986 Jan 1       Impact factor: 49.962

6.  Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.

Authors:  J L Grem; C J Allegra
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

7.  Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.

Authors:  C Benz; M DeGregorio; S Saks; N Sambol; W Holleran; R Ignoffo; B Lewis; E Cadman
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

8.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

9.  Incorporation of a potent antileukemic agent, 5-aza-2'-deoxycytidine, into DNA of cells from leukemic mice.

Authors:  J Veselý; A Cihák
Journal:  Cancer Res       Date:  1977-10       Impact factor: 12.701

10.  Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens.

Authors:  A P Albino; K O Lloyd; A N Houghton; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

View more
  6 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

2.  Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.

Authors:  N E Scholpa; R T Kolli; M Moore; R D Arnold; T C Glenn; B S Cummings
Journal:  Chem Biol Interact       Date:  2016-08-16       Impact factor: 5.192

3.  Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.

Authors:  Susan G Urba; Kari Chansky; Peter J VanVeldhuizen; Robert E Pluenneke; Jacqueline K Benedetti; John S Macdonald; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

4.  Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.

Authors:  C J van Moorsel; H M Pinedo; G Veerman; A M Bergman; C M Kuiper; J B Vermorken; W J van der Vijgh; G J Peters
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

5.  2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.

Authors:  J A Ellerhorst; P Frost; J L Abbruzzese; R A Newman; Y Chernajovsky
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

Review 6.  Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers.

Authors:  Maria Gracia-Hernandez; Zuleima Munoz; Alejandro Villagra
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.